Conference Background

The global pharmaceutical industry is accelerating its shift toward intelligence, green development and high‑efficiency production. Amid rapid R‑D progress of innovative and high‑end preparations alongside an evolving pharmaceutical regulatory framework, continuous‑manufacturing technology has gained widespread industry attention thanks to its merits of high productivity, consistent product quality and low resource‑consumption, ushering in unprecedented development prospects. Nevertheless, the sector still faces pressing issues: advancing practical technology deployment, optimizing processes and equipment, striking a balance between costs and benefits, and achieving large‑scale commercial application in compliance with regulatory requirements.

Event Highlights

At the national debut launch of Chanse Technology’s continuous manufacturing production line for solid dosage preparations, Mr. He Zhizhen, Chairman of the company, opened his speech with patients’ real confusion about drug quality variations, which immediately struck a chord with all pharmaceutical practitioners present. His opening laid bare the long-standing production challenges plaguing the traditional pharmaceutical industry.

In conventional solid dosage production, steady control over key parameters such as blending uniformity and granule properties has long been a priority for industry optimization. Studies indicate that even when complying with pharmacopoeia standards, batch manufacturing may still cause batch-to-batch fluctuations in active ingredient content due to cumulative deviations across multiple procedures, undermining drug consistency — this serves as the core driving force for industrial upgrading.Besides, the traditional model faces the dual pressures of environmental compliance and cost-efficiency enhancement: high energy consumption during production, intractable waste disposal, and lengthy production cycles that drive up overall costs, making it difficult to adapt to the sustainable development needs of the pharmaceutical industry.

According to Mr. He, equipped with full-process intelligent control and real-time quality monitoring, Chanse Technology’s continuous manufacturing production line achieves precise consistency of solid dosage products from the first tablet to the very last. It provides a new technical solution for improving pharmaceutical quality stability, and pushes the industry forward from "compliance assurance" to "precision smart manufacturing".This technology also delivers remarkable benefits in cost reduction, efficiency improvement and green development. Continuous production shortens manufacturing cycles and reduces manual intervention, thus lowering overall energy consumption and material loss; intelligent regulation cuts waste discharge, helping pharmaceutical enterprises reach low-carbon production and sustainable development goals.

What Is Continuous Manufacturing?Continuous manufacturing is an industrial production mode in which raw materials pass through a series of processing steps in a constant, uninterrupted flow throughout the production process. Compared with traditional batch manufacturing (intermittent production carried out batch by batch), its core features include non-stop production flow, high automation, and stable material and energy streams, making it ideal for large-scale production of standardized products.

The transformation brought by continuous manufacturing is all-encompassing. To reach an annual output of 20 billion tablets, a traditional factory requires 20,000 square meters of space, while Chanse Technology can achieve the same capacity with only 3,000 square meters of cleanroom area. Costs for R&D, plant construction and labor are all reduced by approximately 80%, striking a win-win balance between low resource consumption and environmental protection targets. More importantly, it completely redefines pharmaceutical quality standards.

Mr. He emphasized, "Traditional batch manufacturing only delivers a 'probability of compliance', while continuous manufacturing delivers '100% certainty'." This certainty is the fundamental confidence to counter disease risks with stable drug quality, and embodies pharmaceutical professionals’ original aspiration of safeguarding every patient.The continuous manufacturing production line brings threefold value to the industry:For pharmaceutical enterprises: it delivers cost reduction, efficiency gains and green production;For regulatory authorities: real-time data and standardized production improve regulatory efficiency and reinforce the drug safety defense line;For patients: it fulfills the core demand for safe medication and stable therapeutic efficacy.

Now, this nationally premiered continuous manufacturing production line has been officially unveiled. Are you ready to join hands with Chanse to lead industry transformation through technological innovation, and deliver a more reliable health commitment to hundreds of millions of patients?